Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’

RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.

Medical technology, telemedicine, e-health, medical online, electronics health record system concept. male doctor working on digital tablet computer with web icons technology on virtual screen.
A Patient Experience Data Checklist For Review Summaries

The US Food and Drug Administration is making progress with its implementation of a patient experience data summary section in new drug review documents but there are still inconsistencies, RTI Health Solutions' Ari Gnanasakthy reported at ISPOR's recent annual meeting.

The patient experience data table outlines whether and what patient experience data had been submitted with an application. The FDA began using the table in 2017 to help meet a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

More from Agency Leadership